Select Publications

By Dr Andrew On Wah Yam

Journal articles

Crumbaker M; Shekar S; Lawrence MG; Goldstein LD; Yam AO; Downton T; Begbie S; Zielinski R; Fox W; Araiza N; Yousif J; Ratnayake L; Antonarakis ES; Denmeade SR; Joshua AM, 2025, 'A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).', Journal of Clinical Oncology, 43, pp. 218 - 218, http://dx.doi.org/10.1200/jco.2025.43.5_suppl.218

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua AM; Emmett L; Horvath L; Murphy DG; Hsiao E; Balakrishnar B; Lin P; Redfern A; Macdonald W; Ng S; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS; Akhurst T; Alipour R; Au L; Banks P; Emerson B; Hussain N; Haskali M; Lewin J; Linklater R; Kostos L; Kashyap R; Krishanth P; Kong G; Kumar A; Murphy D; Roselt P; Sandhu S; Scalzo M; Tran B; Wallace R; Spain L; Bourke H; Milton A; Russo D; Bills M; Chew C; Hsieh W; Crouch B; Smyth D; Pandelus S; Lam H; Gan C; Goh J; Scott A; Hafeez U; Ackermann U; Young K; Poon A; Pathmaraj K; Schembri G; Roach P; Bailey D; Hung T; Asad A; Hagan T; Watts J; Campbell E; Chua W; Pal A; Crumbaker M; Nguyen A; Yam A; Chen J; Ardolino L; Kongrak K; Ratnayake L, 2024, 'Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', Lancet Oncology, 25, pp. 1267 - 1276, http://dx.doi.org/10.1016/S1470-2045(24)00440-6

Yam AO; Jakovija A; Gatt C; Chtanova T, 2024, 'Neutrophils under the microscope: neutrophil dynamics in infection, inflammation, and cancer revealed using intravital imaging', Frontiers in Immunology, 15, http://dx.doi.org/10.3389/fimmu.2024.1458035

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, 'Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy', Cancer Research, 83, pp. 1315 - 1328, http://dx.doi.org/10.1158/0008-5472.CAN-21-4025

Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L, 2023, 'Evaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398

John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L, 2023, '177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677

Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L, 2023, 'The Prognostic Value of Posttreatment ⁶⁸Ga-PSMA-11 PET/CT and ¹⁸F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with ¹⁷⁷Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L, 2022, '177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566, http://dx.doi.org/10.2967/jnumed.121.262552

Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L, 2021, 'Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European Urology Oncology, 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002

Yam AO; Chtanova T, 2020, 'Imaging the neutrophil: Intravital microscopy provides a dynamic view of neutrophil functions in host immunity', Cellular Immunology, 350, http://dx.doi.org/10.1016/j.cellimm.2019.01.003

Yam A; Bailey J; Lin F; Jakovija A; Counoupas C; Triccas J; Gunzer M; Bald T; Grey S; Chtanova T, 2020, 'Microbial activation converts neutrophils into anti-tumor effectors', , http://dx.doi.org/10.1101/2020.08.21.259051

Yam AO; Chtanova T, 2019, 'The ins and outs of chemokine-mediated immune cell trafficking in skin cancer', Frontiers in Immunology, 10, http://dx.doi.org/10.3389/fimmu.2019.00386

Yam A; Barnet M; Mersiades A; Gao B; Kao S; Boyer M; Hui R; Nagrial A, 2017, 'P3.02c-055 Incidence and Grade of Pneumonitis in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Anti-PD-1 Antibodies', Journal of Thoracic Oncology, 12, pp. S1308 - S1308, http://dx.doi.org/10.1016/j.jtho.2016.11.1850

Tan B; Zammit NW; Yam A; Slattery RM; Walters SN; Malle E; Grey ST, 2013, 'Baculoviral inhibitors of apoptosis repeat containing (BIRC) proteins fine-tune TNF-induced nuclear factor êb and c-Jun N-terminal kinase signalling in mouse pancreatic beta cells', Diabetologia, 56, pp. 520 - 532, http://dx.doi.org/10.1007/s00125-012-2784-x

Yam AO; Andresen D; Kesson AM; Isaacs D, 2009, 'Incidence of sterile cerebrospinal fluid pleocytosis in infants with urinary tract infection', Journal of Paediatrics and Child Health, 45, pp. 364 - 367, http://dx.doi.org/10.1111/j.1440-1754.2009.01502.x

Liuwantara D; Gunton J; Yam A; Walters S; Marino E; McShea A; Grey S, 2008, 'GENERATING ISLET ALLOGRAFT TOLERANCE BY BLOCKING NF-KB ACTIVATION AND PREVENTING APOPTOSIS.', Transplantation, 86, pp. 18 - 18, http://dx.doi.org/10.1097/01.tp.0000332732.20615.8f

Liuwantara D; Elliot M; Smith MA; Yam A; Walters SN; Marino E; McShea A; Grey S, 2006, 'Nuclear Factor-KB regulates beta-cell death - A critical role for A20 in beta-cell protection', Diabetes, 55, pp. 2491 - 2501

Ritchie AJ; Yam A; Tanabe K; Rice SA; Cooley MA, 2003, 'Modification of in viro and in vitro T- and B-Cell-Mediated Immune Responses by the Pseudomonas aeruginosa Quorum-Sensing Molecule N-(3-Oxododecanoyl)-L-Homoserine Lactone', Infection and Immunity, 71, pp. 4421 - 4431

Ritchie AJ; Yam AOW; Tanabe KM; Rice SA; Cooley MA, 2003, 'Modification of in vivo and in vitro T- and B-cell-mediated immune responses by the Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)-L-homoserine lactone', INFECTION AND IMMUNITY, 71, pp. 4421 - 4431, http://dx.doi.org/10.1128/IAI.71.8.4421-4431.2003

Conference Papers

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302400&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000529525900189&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Yam A; Barnet M; Mersiades A; Gao B; Kao S; Boyer M; Hui R; Nagrial A, 2017, 'Incidence and Grade of Pneumonitis in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Anti-PD-1 Antibodies', in JOURNAL OF THORACIC ONCOLOGY, ELSEVIER SCIENCE INC, pp. S1308 - S1308, http://dx.doi.org/10.1016/j.jtho.2016.11.1850

Yam AO; Mersiadis A; Gao B; Hui R; Nagrial A, 2016, 'INCIDENCE AND GRADE OF PNEUMONITIS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH ANTI-PD1 ANTIBODIES', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 71 - 72

Liuwantara D; Elliot M; Smith M; Walters SN; Marino E; Yam AO; Mcshea A; Grey ST, 2007, 'Nf-kb regulates b-cell death: A critical role for early immediate response genes in b-cell protection', in DIABETES, AMER DIABETES ASSOC, IL, Chicago, pp. A411 - A412, presented at 67th Annual Meeting of the American-Diabetes-Association, IL, Chicago, 22 June 2007 - 26 June 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000246930202515&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Niman R; Wilson P; Sharma S; Ayers M; Eu P; Stockler MR; Martin AJ; Joshua AM; Emmett L, 2022, 'Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1(77)LuPSMA-617 and NOX66 (LuPIN).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 40, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.166

Lau B; Crumbaker M; Yam AOW; Marastoni S; Luckhurst M; O'Grady A; Wouters B; Joshua AM, 2021, 'A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, Vol. 39, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.114

Pathmanandavel S; Crumbaker M; Yam AOW; Rofe C; Ho B; Chan WL; Sharma S; Hickey AJ; Kongrak K; Ratnayake L; Kwan EM; Azad A; Eu P; Nguyen A; Joshua AM; Emmett L, 2021, 'Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at ASCO Genitourinary Cancers Symposium (GU ASCO), ELECTR NETWORK, 11 February 2021 - 13 February 2021, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.103

Other

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Data from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.c.6599657

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 1 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027266.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 2 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027263

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 3 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027260

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 4 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027257

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Supplementary Data from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027254

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Supplementary Table 1 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027251

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Data from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.c.6599657.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633202

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633199.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633196.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.22633193.v1

Back to profile page

Filter by type

View all »

ORCID as entered in ROS

https://orcid.org/0000-0001-8153-7544